Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

PloS One
Waranya RattanavipapongYot Teerawattananon

Abstract

Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care's benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impact of introducing sofosbuvir-based regimens in the tax-based health insurance scheme. The Markov model was constructed to assess costs and benefits of the four treatment options that include: (i) current practice-peginterferon alfa (PEG) and ribavirin (RBV) for 24 weeks in genotype 3 and 48 weeks for other genotypes; (ii) Sofosbuvir plus peginterferon alfa and ribavirin (SOF+PEG-RBV) for 12 weeks; (iii) Sofosbuvir and daclatasvir (SOF+DCV) for 12 weeks; (iv) Sofosbuvir and ledipasvir (SOF+LDV) for 12 weeks for non-3 genotypes and SOF+PEG-RBV for 12 weeks for genotype 3 infection. Given that policy options (ii) and (iii) are for pan-genotypic infection, the cost of genotype testing was applied only for policy options (i) and (iv). Results reveal that all sofosbuvir-based regimens had greater quality adjusted life years (QALY) gains compared with the current treatment, therefore associated with lower lifetime costs and more favourable health outcom...Continue Reading

References

Jan 20, 2006·Liver International : Official Journal of the International Association for the Study of the Liver·Ming-Lung YuWan-Long Chuang
Apr 15, 2006·International Journal of Medical Sciences·Stephen L Chen, Timothy R Morgan
Mar 28, 2008·The Korean Journal of Hepatology·Kyoung-Tae KimMyung-Hwan Roh
May 30, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ming-Lung YuWan-Long Chuang
Jul 29, 2008·The Journal of Infectious Diseases·James FungMan-Fung Yuen
Oct 7, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chen-Hua LiuJia-Horng Kao
Apr 24, 2013·The New England Journal of Medicine·Eric LawitzEdward J Gane
Jan 17, 2014·The New England Journal of Medicine·Mark S SulkowskiUNKNOWN AI444040 Study Group
Jan 17, 2014·The New England Journal of Medicine·Kris V KowdleyBarry Bernstein
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
Jul 30, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jane P MessinaEleanor Barnes
Dec 8, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Louis S MatzaDavid H Feeny
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David R NelsonUNKNOWN ALLY-3 Study Team
Oct 18, 2015·The Lancet Global Health·Isabelle Andrieux-MeyerSaeed S Hamid
May 1, 2014·Value in Health Regional Issues·Satawat ThongsawatDittaya Thongsuk

❮ Previous
Next ❯

Citations

Nov 10, 2018·Current Medical Research and Opinion·Bin WuQing Xie

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

NLEM
STATA

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.